Indication: Hematological Malignancies
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Lymphoma
Sub-indication: follicular, marginal zone and mantle cell lymphoma
Line of Therapy: FL-third line; MZL & MCL-second line
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: TG Therapeutics, Inc
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org
